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journal homepage: www.elsevier .com/locate/rmedLETTER TO THE EDITORResponse to “MtDNA depletions and
deletions may also important in
pathogenesis of lung cancer”We appreciate the interest of Emin Akgul et al. in our
research on mtDNA mutations in exhaled breath condensate
in patients with lung cancer [1]. As the authors of this letter
indicated, large scale deletions and mtDNA depletions have
also been implicated in the pathogenesis of cancer devel-
opment as in given examples of KearneSayre syndrome and
Alper’s syndrome, and furthermore that these have been
investigated in studies of lung cancer. Our study was
intended to be a pilot study looking at mtDNA changes in
EBC of lung cancer patients, and we chose the D-loop as a
region to study as it is a hotspot of point mutations in a
variety of cancers, including lung cancer [2]. Furthermore,
previous literature has suggested that frequency of D-loop
mutations correlated with tumour grade and lymph node
metastases, suggesting that analysis of D-loop mutations
may have prognostic value [3].
We agree that it would be interesting to study large
scale deletions and mtDNA copy number changes both as a
reflection of oxidative damage and as a cause of production
of reactive oxygen species which have been implicated in
carcinogenesis. In a prospective study higher mtDNA copy
number has been associated with risk of developing lung
cancer [4], however a commonly studied 4977-bp deletion
in mtDNA was not demonstrated to be associated with an
increased risk of lung cancer [5] despite being higher in
bronchoalveolar tissues of smokers [6].
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